TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
-9.39%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$982M
AUM Growth
+$21.4M
(+2.2%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
17.18%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$28.1M |
| 2 |
ANI Pharmaceuticals
ANIP
|
$19.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$15.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$14.9M |
| 5 |
CRISPR Therapeutics
CRSP
|
$10.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$14.5M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$9.44M |
| 4 |
Intellia Therapeutics
NTLA
|
$5.5M |
| 5 |
BLUE
bluebird bio
BLUE
|
$3.2M |
Sector Composition
| 1 | Healthcare | 95.92% |
| 2 | Technology | 1.53% |
| 3 | Real Estate | 0.71% |
| 4 | Communication Services | 0.66% |
| 5 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vanda Pharmaceuticals
VNDA
$274M
| $12.2M | 1.24% |
2,153,307
+401,653
| +23% | +$2.27M |
|
27
Outlook Therapeutics
OTLK
$39.5M
| $12M | 1.22% |
1,619,412
| – | – |
|
28
AstraZeneca
AZN
$254B
| $11.7M | 1.19% |
150,000
| – | – |
|
29
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $11.7M | 1.19% |
625,309
+125,309
| +25% | +$2.34M |
|
30
Nuvation Bio
NUVB
$1.17B
| $11M | 1.12% |
3,751,864
+200,000
| +6% | +$584K |
|
31
Applied Therapeutics
APLT
$67M
| $10.9M | 1.11% |
2,330,000
+100,000
| +4% | +$467K |
|
32
Adicet Bio
ACET
$59.4M
| $9.94M | 1.01% |
8,216,960
+1,809,560
| +28% | +$2.19M |
|
33
Teladoc Health
TDOC
$1.35B
| $9.78M | 1% |
+1,000,000
| New | +$9.78M |
|
34
CytomX Therapeutics
CTMX
$346M
| $9.51M | 0.97% |
7,791,936
+1,341,936
| +21% | +$1.64M |
|
|
CRGX
35
DELISTED
CARGO Therapeutics
CRGX
| $9.4M | 0.96% |
572,697
+105,888
| +23% | +$1.74M |
|
36
Zymeworks
ZYME
$1.07B
| $9.36M | 0.95% |
1,100,000
| – | – |
|
37
Immunome
IMNM
$853M
| $8.71M | 0.89% |
720,000
| – | – |
|
38
Harmony Biosciences
HRMY
$2.09B
| $8.48M | 0.86% |
281,200
| – | – |
|
|
ELEV
39
DELISTED
Elevation Oncology
ELEV
| $8.26M | 0.84% |
3,060,000
| – | – |
|
40
Biogen
BIIB
$20.5B
| $8.11M | 0.83% |
+35,000
| New | +$8.11M |
|
41
Black Diamond Therapeutics
BDTX
$163M
| $7.47M | 0.76% |
1,603,200
| – | – |
|
42
Replimune Group
REPL
$454M
| $7.25M | 0.74% |
+805,440
| New | +$7.25M |
|
43
Ventyx Biosciences
VTYX
$185M
| $7.16M | 0.73% |
3,100,000
| – | – |
|
44
Ionis Pharmaceuticals
IONS
$9.46B
| $7.15M | 0.73% |
150,000
| – | – |
|
45
Dianthus Therapeutics
DNTH
$794M
| $6.85M | 0.7% |
264,692
| – | – |
|
46
Insmed
INSM
$30.1B
| $6.7M | 0.68% |
+100,000
| New | +$6.7M |
|
47
Heron Therapeutics
HRTX
$202M
| $6.48M | 0.66% |
1,850,000
| – | – |
|
48
Viking Therapeutics
VKTX
$2.98B
| $6.36M | 0.65% |
120,000
+20,000
| +20% | +$1.06M |
|
49
Beam Therapeutics
BEAM
$1.88B
| $6.33M | 0.64% |
+270,000
| New | +$6.33M |
|
50
Precision BioSciences
DTIL
$59.3M
| $6.07M | 0.62% |
623,332
+33,763
| +6% | +$329K |
|